Pub Date : 2025-05-12DOI: 10.1038/s41568-025-00828-5
Xinyuan Bi
In this Tools of the Trade article, Xinyuan Bi describes the development of digital colloid-enhanced Raman spectroscopy (dCERS), a method that addresses the reproducibility issues of surface-enhanced Raman spectroscopy (SERS) at ultra-low concentrations by using single-molecule counting.
{"title":"Digitally enhanced Raman spectroscopy","authors":"Xinyuan Bi","doi":"10.1038/s41568-025-00828-5","DOIUrl":"10.1038/s41568-025-00828-5","url":null,"abstract":"In this Tools of the Trade article, Xinyuan Bi describes the development of digital colloid-enhanced Raman spectroscopy (dCERS), a method that addresses the reproducibility issues of surface-enhanced Raman spectroscopy (SERS) at ultra-low concentrations by using single-molecule counting.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 8","pages":"569-569"},"PeriodicalIF":66.8,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143933462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-28DOI: 10.1038/s41568-025-00823-w
Ali Yasin Sonay
Ali Sonay describes the development of an image-guided surgical approach that uses a commercially available dye, CJ215, to improve the real-time detection and precise removal of cancerous tissues and for better preclinical visualization of cancer progression in deep tissues.
Ali Sonay描述了一种图像引导手术方法的发展，该方法使用市上可用的染料CJ215，以改善癌组织的实时检测和精确切除，并更好地对深部组织的癌症进展进行临床前可视化。
{"title":"Deep tissue imaging of cancer in the infrared","authors":"Ali Yasin Sonay","doi":"10.1038/s41568-025-00823-w","DOIUrl":"10.1038/s41568-025-00823-w","url":null,"abstract":"Ali Sonay describes the development of an image-guided surgical approach that uses a commercially available dye, CJ215, to improve the real-time detection and precise removal of cancerous tissues and for better preclinical visualization of cancer progression in deep tissues.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 8","pages":"570-570"},"PeriodicalIF":66.8,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143880638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-25DOI: 10.1038/s41568-025-00817-8
Matthias Hinterndorfer, Valentina A. Spiteri, Alessio Ciulli, Georg E. Winter
Targeted protein degradation (TPD) aims at reprogramming the target specificity of the ubiquitin–proteasome system, the major cellular protein disposal machinery, to induce selective ubiquitination and degradation of therapeutically relevant proteins. Since its conception over 20 years ago, TPD has gained a lot of attention mainly due to improvements in the design of bifunctional proteolysis targeting chimeras (PROTACs) and understanding the mechanisms underlying molecular glue degraders. Today, PROTACs are on the verge of a first clinical approval and recent structural and mechanistic insights combined with technological leaps promise to unlock the rational design of protein degraders, following the lead of lenalidomide and related clinically approved analogues. At the same time, the TPD universe is expanding at a record speed with the discovery of novel modalities beyond molecular glue degraders and PROTACs. Here we review the recent progress in the field, focusing on newly discovered degrader modalities, the current state of clinical degrader candidates for cancer therapy and upcoming design approaches. Targeted protein degradation (TPD) is an emerging pharmacological modality in cancer therapy. In this Review, Hinterndorfer et al. outline the mechanistic bases of TPD and discuss the characteristics, advantages and applications of established compounds as well as upcoming classes of degraders.
{"title":"Targeted protein degradation for cancer therapy","authors":"Matthias Hinterndorfer, Valentina A. Spiteri, Alessio Ciulli, Georg E. Winter","doi":"10.1038/s41568-025-00817-8","DOIUrl":"10.1038/s41568-025-00817-8","url":null,"abstract":"Targeted protein degradation (TPD) aims at reprogramming the target specificity of the ubiquitin–proteasome system, the major cellular protein disposal machinery, to induce selective ubiquitination and degradation of therapeutically relevant proteins. Since its conception over 20 years ago, TPD has gained a lot of attention mainly due to improvements in the design of bifunctional proteolysis targeting chimeras (PROTACs) and understanding the mechanisms underlying molecular glue degraders. Today, PROTACs are on the verge of a first clinical approval and recent structural and mechanistic insights combined with technological leaps promise to unlock the rational design of protein degraders, following the lead of lenalidomide and related clinically approved analogues. At the same time, the TPD universe is expanding at a record speed with the discovery of novel modalities beyond molecular glue degraders and PROTACs. Here we review the recent progress in the field, focusing on newly discovered degrader modalities, the current state of clinical degrader candidates for cancer therapy and upcoming design approaches. Targeted protein degradation (TPD) is an emerging pharmacological modality in cancer therapy. In this Review, Hinterndorfer et al. outline the mechanistic bases of TPD and discuss the characteristics, advantages and applications of established compounds as well as upcoming classes of degraders.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 7","pages":"493-516"},"PeriodicalIF":66.8,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143875881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-24DOI: 10.1038/s41568-025-00821-y
Dimple Notani
In this Journal Club, Dimple Notani discusses a study that demonstrates a tumour suppressive function of the androgen receptor in oestrogen receptor-positive breast cancer.
{"title":"Androgen receptor activation for breast cancer therapy","authors":"Dimple Notani","doi":"10.1038/s41568-025-00821-y","DOIUrl":"10.1038/s41568-025-00821-y","url":null,"abstract":"In this Journal Club, Dimple Notani discusses a study that demonstrates a tumour suppressive function of the androgen receptor in oestrogen receptor-positive breast cancer.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 6","pages":"398-398"},"PeriodicalIF":66.8,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143866328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-23DOI: 10.1038/s41568-025-00822-x
Clare Puttick
In this Tools of the Trade article, Clare Puttick describes the development of MHC Hammer, a computational tool that uses whole-exome sequencing and RNA sequencing data for measuring HLA disruption.
{"title":"Measuring HLA disruption using MHC Hammer","authors":"Clare Puttick","doi":"10.1038/s41568-025-00822-x","DOIUrl":"10.1038/s41568-025-00822-x","url":null,"abstract":"In this Tools of the Trade article, Clare Puttick describes the development of MHC Hammer, a computational tool that uses whole-exome sequencing and RNA sequencing data for measuring HLA disruption.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 7","pages":"489-489"},"PeriodicalIF":66.8,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-22DOI: 10.1038/s41568-025-00814-x
Kamila Naxerova
The evolution of metastasis in humans is considerably less well understood than the biology of early carcinogenesis. For over a century, clinicians and scientists have been debating whether metastatic potential is the intrinsic property of a cancer, pre-determined by the molecular characteristics of the tumour founder cell, or whether metastatic capacity evolves in a stepwise fashion as the tumour grows, akin to the multistage accumulation of oncogenic alterations that give rise to the first cancer cell. In this Perspective, I examine how genetic analyses of primary tumours and matched metastases can distinguish between these two competing metastasis evolution models, with particular emphasis on the utility of metastatic randomness — a quantitative measure that reflects whether metastases arise from a random selection of primary tumour subclones or whether they are enriched for descendants of privileged lineages that have acquired pro-metastatic traits. Probable metastasis evolution trajectories in tumours with high and low baseline metastatic capacity are discussed, along with the role of seeding rates and selection at different metastatic host sites. Finally, I argue that trailblazing insights into human metastasis biology are immediately possible if we make a concerted effort to apply existing experimental and theoretical tools to the right patient cohorts. In this Perspective, Kamila Naxerova discusses how genetic analyses of primary tumours and matched metastases can distinguish between competing metastasis evolution models, arguing that further insights into human metastasis biology could be enabled by a framework that rigorously quantifies whether metastases descend from a nonrandom selection of primary tumour lineages.
{"title":"Evolutionary paths towards metastasis","authors":"Kamila Naxerova","doi":"10.1038/s41568-025-00814-x","DOIUrl":"10.1038/s41568-025-00814-x","url":null,"abstract":"The evolution of metastasis in humans is considerably less well understood than the biology of early carcinogenesis. For over a century, clinicians and scientists have been debating whether metastatic potential is the intrinsic property of a cancer, pre-determined by the molecular characteristics of the tumour founder cell, or whether metastatic capacity evolves in a stepwise fashion as the tumour grows, akin to the multistage accumulation of oncogenic alterations that give rise to the first cancer cell. In this Perspective, I examine how genetic analyses of primary tumours and matched metastases can distinguish between these two competing metastasis evolution models, with particular emphasis on the utility of metastatic randomness — a quantitative measure that reflects whether metastases arise from a random selection of primary tumour subclones or whether they are enriched for descendants of privileged lineages that have acquired pro-metastatic traits. Probable metastasis evolution trajectories in tumours with high and low baseline metastatic capacity are discussed, along with the role of seeding rates and selection at different metastatic host sites. Finally, I argue that trailblazing insights into human metastasis biology are immediately possible if we make a concerted effort to apply existing experimental and theoretical tools to the right patient cohorts. In this Perspective, Kamila Naxerova discusses how genetic analyses of primary tumours and matched metastases can distinguish between competing metastasis evolution models, arguing that further insights into human metastasis biology could be enabled by a framework that rigorously quantifies whether metastases descend from a nonrandom selection of primary tumour lineages.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 7","pages":"545-560"},"PeriodicalIF":66.8,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-16DOI: 10.1038/s41568-025-00818-7
Christopher Lowden
In this Tools of the Trade article, Christopher Lowden describes the development and use of CRISPR-StAR, which leverages internal controls to overcome experimental noise for improved in vivo functional genomic screens.
{"title":"CRISPR-StAR to transform in vivo functional genomic screening","authors":"Christopher Lowden","doi":"10.1038/s41568-025-00818-7","DOIUrl":"10.1038/s41568-025-00818-7","url":null,"abstract":"In this Tools of the Trade article, Christopher Lowden describes the development and use of CRISPR-StAR, which leverages internal controls to overcome experimental noise for improved in vivo functional genomic screens.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 6","pages":"395-395"},"PeriodicalIF":66.8,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143836642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-10DOI: 10.1038/s41568-025-00803-0
Kathryn L. Simpson, Dominic G. Rothwell, Fiona Blackhall, Caroline Dive
Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with ~7% 5-year overall survival reflecting early metastasis and rapid acquired chemoresistance. Immunotherapy briefly extends overall survival in ~15% cases, yet predictive biomarkers are lacking. Targeted therapies are beginning to show promise, with a recently approved delta-like ligand 3 (DLL3)-targeted therapy impacting the treatment landscape. The increased availability of patient-faithful models, accumulating human tumour biobanks and numerous comprehensive molecular profiling studies have collectively facilitated the mapping and understanding of substantial intertumoural and intratumoural heterogeneity. Beyond the almost ubiquitous loss of wild-type p53 and RB1, SCLC is characterized by heterogeneously mis-regulated expression of MYC family members, yes-associated protein 1 (YAP1), NOTCH pathway signalling, anti-apoptotic BCL2 and epigenetic regulators. Molecular subtypes are based on the neurogenic transcription factors achaete-scute homologue 1 (ASCL1) and neurogenic differentiation factor 1 (NEUROD1), the rarer non-neuroendocrine transcription factor POU class 2 homeobox 3 (POU2F3), and immune- and inflammation-related signatures. Furthermore, SCLC shows phenotypic plasticity, including neuroendocrine-to-non-neuroendocrine transition driven by NOTCH signalling, which is associated with disease progression, chemoresistance and immune modulation and, in mouse models, with metastasis. Although these features pose substantial challenges, understanding the molecular vulnerabilities of transcription factor subtypes, the functional relevance of plasticity and cell cooperation offer opportunities for personalized therapies informed by liquid and tissue biomarkers. In this Review, Simpson et al. summarize the emergent understanding of molecular subtypes of small cell lung cancer (SCLC). They discuss how intratumour heterogeneity and dynamic tumour plasticity may challenge the success of immune and molecular subtype-targeted therapies and argue that combination therapies, monitored by serial liquid biopsy-based biomarkers, will be needed to improve the outcomes of patients with SCLC.
{"title":"Challenges of small cell lung cancer heterogeneity and phenotypic plasticity","authors":"Kathryn L. Simpson, Dominic G. Rothwell, Fiona Blackhall, Caroline Dive","doi":"10.1038/s41568-025-00803-0","DOIUrl":"10.1038/s41568-025-00803-0","url":null,"abstract":"Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with ~7% 5-year overall survival reflecting early metastasis and rapid acquired chemoresistance. Immunotherapy briefly extends overall survival in ~15% cases, yet predictive biomarkers are lacking. Targeted therapies are beginning to show promise, with a recently approved delta-like ligand 3 (DLL3)-targeted therapy impacting the treatment landscape. The increased availability of patient-faithful models, accumulating human tumour biobanks and numerous comprehensive molecular profiling studies have collectively facilitated the mapping and understanding of substantial intertumoural and intratumoural heterogeneity. Beyond the almost ubiquitous loss of wild-type p53 and RB1, SCLC is characterized by heterogeneously mis-regulated expression of MYC family members, yes-associated protein 1 (YAP1), NOTCH pathway signalling, anti-apoptotic BCL2 and epigenetic regulators. Molecular subtypes are based on the neurogenic transcription factors achaete-scute homologue 1 (ASCL1) and neurogenic differentiation factor 1 (NEUROD1), the rarer non-neuroendocrine transcription factor POU class 2 homeobox 3 (POU2F3), and immune- and inflammation-related signatures. Furthermore, SCLC shows phenotypic plasticity, including neuroendocrine-to-non-neuroendocrine transition driven by NOTCH signalling, which is associated with disease progression, chemoresistance and immune modulation and, in mouse models, with metastasis. Although these features pose substantial challenges, understanding the molecular vulnerabilities of transcription factor subtypes, the functional relevance of plasticity and cell cooperation offer opportunities for personalized therapies informed by liquid and tissue biomarkers. In this Review, Simpson et al. summarize the emergent understanding of molecular subtypes of small cell lung cancer (SCLC). They discuss how intratumour heterogeneity and dynamic tumour plasticity may challenge the success of immune and molecular subtype-targeted therapies and argue that combination therapies, monitored by serial liquid biopsy-based biomarkers, will be needed to improve the outcomes of patients with SCLC.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 6","pages":"447-462"},"PeriodicalIF":66.8,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143813620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-08DOI: 10.1038/s41568-025-00815-w
Bercin Cenik
In this Tools of the Trade article, Bercin Cenik describes the development and use of TurboCas, an enzyme that pairs catalytically dead Cas9 with the proximity-labelling enzyme miniTurbo to map the regulatory proteins that shape transcription.
{"title":"TurboCas for locus-specific proximity labelling","authors":"Bercin Cenik","doi":"10.1038/s41568-025-00815-w","DOIUrl":"10.1038/s41568-025-00815-w","url":null,"abstract":"In this Tools of the Trade article, Bercin Cenik describes the development and use of TurboCas, an enzyme that pairs catalytically dead Cas9 with the proximity-labelling enzyme miniTurbo to map the regulatory proteins that shape transcription.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 6","pages":"396-396"},"PeriodicalIF":66.8,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143805930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-04DOI: 10.1038/s41568-025-00816-9
Daniela Senft
The mechanisms of how pH-dependent cell death, alkaliptosis, is regulated are incompletely understood. Chen et al. now demonstrate that the cholesterol biosynthesis protein CYP51A1 suppresses alkaliptosis induced by the opioid analgesic JTC801.
{"title":"Blocking cholesterol biosynthesis to clean out cancer","authors":"Daniela Senft","doi":"10.1038/s41568-025-00816-9","DOIUrl":"10.1038/s41568-025-00816-9","url":null,"abstract":"The mechanisms of how pH-dependent cell death, alkaliptosis, is regulated are incompletely understood. Chen et al. now demonstrate that the cholesterol biosynthesis protein CYP51A1 suppresses alkaliptosis induced by the opioid analgesic JTC801.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"25 5","pages":"321-321"},"PeriodicalIF":66.8,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：